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Angiotensin III up-regulates genes involved in kidney damage in
mesangial cells and renal interstitial fibroblasts. Angiotensin
(Ang) II is considered the effector peptide of the renin-angioten-
sin system (RAS) that acts as a renal growth factor. Some studies
have shown that the angiotensin degradation product Ang III
presents some biological activities, though its role in renal pathol-
ogy has not been explored. We have observed that in renal
interstitial fibroblasts Ang III induces c-fos gene expression,
suggesting a potential role of Ang III in the control of cell
proliferation. To study the involvement of Ang III in matrix
regulation, we determined whether Ang III increased TGF-b gene
expression and fibronectin production in cultured rat mesangial
cells and renal interstitial fibroblasts, the main effector cells in
glomerular and interstitial fibrosis, respectively. In both cell types,
treatment with Ang III (1027 M) for six hours up-regulated gene
expression of transforming growth factor-b1 (TGF-b1; 2.3- and
2.2-fold, respectively). This peptide also increased fibronectin
production in renal interstitial fibroblasts. All these data suggest
that Ang III could contribute to matrix accumulation. Activation
of local RAS has been described during renal damage. Renal cells
express angiotensinogen mRNA that was up-regulated in re-
sponse to Ang II and Ang III stimulation, and therefore both
peptides may participate in the generation of angiotensin peptides
in the kidney. In conclusion, our results suggest that the angio-
tensin degradation product Ang III could participate in the
pathogenesis of key events of renal diseases, supporting the
hypothesis that other peptides of the RAS besides Ang II may be
involved in renal injury.
Angiotensin (Ang) II is a powerful vasoconstrictor agent
that participates in local and systemic hemodynamic regu-
lation. In the last few years, Ang II has been recognized as
a growth factor that plays an active role in renal pathology
[reviewed in 1, 2]. Although Ang II has been considered the
effector peptide of the renin-angiotensin system (RAS),
recent studies suggest that other angiotensin peptides are
bioactive agents [reviewed in 3]. Ang III presents some
physiological functions similar to Ang II in cardiovascular
and central nervous systems, though in some of them, such
as the pressor response, Ang III is less potent than Ang II
[3]. Renal infusion of Ang II and Ang III increased the
fractional clearance of albumin [4]. Ang (1-7) presents
some opposite effects to Ang II, acts as a vasodilator agent
and inhibits vascular smooth muscle cells growth [3]. How-
ever, the potential role of Ang degradation products in
renal pathology is unclear. In addition, some of Ang II
actions seem to be due to these degradation peptides. Thus,
the release of vasopressin requires the conversion of Ang II
to Ang III [5], and the plasminogen activator inhibitor-1
expression induced by Ang II is mediated by Ang IV
through the angiotensin II receptor type-4 (AT4) [6].
The kidney possesses all of the machinery necessary to
generate and degrade the angiotensin peptides. Ang II can
be converted to Ang III by aminopeptidase A (APA)
present in glomeruli and mainly in tubuli [review in 3]. In
the lumen of proximal tubular cells, the concentration of
Ang II is 1000 times higher than in plasma, but due to the
high density of peptidases, it only represents around 5 to
15% of total renal angiotensins [7]. In pathological settings,
the concentration of proteolytic enzymes increases due to
the activation of resident and infiltrating cells. On the other
hand, elevated renal APA mRNA expression has been
found in the glomeruli of animals with several models of
renal injury [8, 9]. All these data support the idea of the
presence of angiotensin degradation products in the kidney
in normal and pathological conditions.
The main features of renal damage are proliferation of
resident cells, excessive accumulation of extracellular ma-
trix and mononuclear cell recruitment [10]. Some authors,
including ourselves, have demonstrated that Ang II partic-
ipates in all of these phenomena, stimulating directly renal
cells to proliferate (mainly mesangial cells and interstitial
fibroblasts), to increase matrix production and to synthesize
chemotactic factors [1, 2, 11–13]. In addition, the in vivo
blockade of Ang II actions by treatment with angiotensin
converting enzyme inhibitors and angiotensin receptor
antagonists decreased the renal lesions and inflammatory
infiltration in several models of renal injury [14–17]. All
these data, together with the fact that in pathological
conditions an increased local Ang II generation exists as
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well as general and specific proteases activation [3],
strongly suggest the presence of Ang II degradation prod-
ucts with the potential to renal damage activity.
The aim of this work is to test the hypothesis that other
peptides of the RAS, such as the degradation product Ang
III, may also participate in the pathogenesis of some key
events associated with the progression of renal damage. For
this reason, we studied whether Ang III regulates cell
growth and matrix production, determining whether this
peptide presents similar or opposing properties to those of
Ang II on such phenomena.
METHODS
Cell cultures
Rat mesangial cells were cultured by several sieving
techniques and characterized as previously described [13].
The NRK 49F cell line (ATCC:CRL1570; American Type
Culture Collection, Rockville, MD, USA) is derived from
rat kidney fibroblasts. Cells were grown in DEMEN with
5% FCS. At confluence, cells grown in 75 cm2 flasks were
made quiescent for 48 hours in serum-free medium, and
then different studies were performed.
Northern blot and polymerase chain reaction
The expression of transcripts for c-fos and TGF-b1 was
determined by Northern blot analysis, while angiotensino-
gen (Ao) gene expression was studied by a semiquantitative
RT-PCR technique as previously described [12]. Briefly,
PCR analysis for angiotensinogen and glyceraldehyde 39-
phosphate dehydrogenase (G3PDH) was conducted in the
following conditions (1 min at 63°/54°C, respectively, 3 min
at 72°C and 1 min at 94°C, 25 cycles). The primers used for
rat angiotensinogen were: (antisense) 59-CCAGCCGG-
GAGGTGCAGT-39and (sense) 59-TTCAGGCCAAGAC-
CTCCC-39, and for G3PDH: (antisense) 59-ATACTGT-
TACTTATACCGATG-39 and (sense) 59-AATGCA-
TCCTGCACCACCAA-39 that yielded products of 308 and
515 bp, respectively. In all experiments control reactions
were done to check for the presence of contaminants. The
DNA products were analyzed on 4% polyacrylamide/urea
gels. The gels were dried and exposed to X-ray films.
Determination of fibronectin synthesis
New fibronectin (FN) synthesis was measured by meta-
bolic labeling with [35S]-methionine and immunoprecipita-
tion with anti-FN antibodies, as previously described [12].
Briefly, quiescent cells were incubated for 24 hours with
Ang II and Ang III in methionine-free culture medium
RPMI with 20 mCi/ml of [35S]-methionine. Then, superna-
tants were immunoprecipitated with an excess of anti-FN
antibody (50 mg) for 16 to 18 hours at 4°C, recovered with
protein A-Sepharose beads (Pharmacia, Uppsala, Sweden),
and were analyzed by PAGE-SDS. FN production was
normalized to DNA content. As a negative control for
immunoprecipitation, isotopic normal rabbit IgG (30 mg/
ml) was used. Recombinant human TGF-b (50 pM) was
employed as positive control for FN synthesis.
Statistical analysis
Results are expressed as the mean 6 SEM Significance
was established using Student’s t-test and analysis of vari-
ance. Differences were considered significant if the P value
was less than 0.05. Autoradiograms were scanned using the
Image Quant densitometer (Molecular Dynamics, Sunny-
vale, CA, USA) and results were expressed as arbitrary
densitometric units relative to 28S intensity bands (North-
ern blot) and G3PDH (RT-PCR).
RESULTS
Ang III induces the expression of growth-related nuclear
proto-oncogene c-fos
To investigate whether Ang III could play a potential
role in the control of cell growth we studied the gene
expression of c-fos, an early response gene that has been
associated with cell proliferation, cellular differentiation,
and hypertrophy [18]. Quiescent renal interstitial fibro-
blasts were stimulated with 1027 M Ang II and Ang III for
one hour. Then, RNA was isolated and c-fos mRNA
expression analyzed by Northern blot. Ang III stimulation
induced c-fos gene expression, similar to Ang II, while this
gene did not appear in control cells (Fig. 1).
Ang III elicits up-regulation of TGF-b gene expression
and fibronectin synthesis
To determine whether Ang III could participate in
matrix regulation we evaluated the effects of Ang III on
TGF-b gene expression, the major cytokine involved in
matrix regulation [19], and on fibronectin synthesis, a
representative matrix protein that is synthesized early
Fig. 1. Angiotensin (Ang) III induces c-fos mRNA expression in renal
interstitial fibroblasts. Cells were incubated with 1027 M Ang III and Ang
II for one hour. Then RNA was extracted and c-fos gene expression was
determined by Northern blot. A representative experiment of two is
shown.
Ruiz-Ortega et al: Angiotensin III in renal damageS-42
during renal damage, preceding collagen deposition and
fiber formation [20]. Mesangial cells and interstitial fibro-
blasts are the main cells involved in glomerular and inter-
stitial fibrosis [10, 21], respectively, and thus we chose them
for our studies.
Cultured mesangial cells and renal interstitial fibroblasts
(NRK 49F) were growth arrested by serum depletion for 48
hours. Cells were incubated in serum-free medium with
Ang III and Ang II (1027 to 10211 M) for six hours. RNA
was then extracted and gene expression was determined by
Northern blot. In renal interstitial fibroblasts, we have
previously shown that Ang II increased the mRNA levels of
TGF-b1 with a maximal peak at six hours of incubation
[12]. In those cells, Ang III up-regulated TGF-b gene
expression with a kinetics and intensity similar to Ang II,
being maximal with 1027 M Ang III after six hours of
incubation (2.2-fold vs. control; Fig. 2A). Exposure of
cultured rat mesangial cells to 1027 M Ang III for six hours
also up-regulated TGF-b1 mRNA levels (2.3-fold) similar
to that observed with Ang II (Fig. 2A).
To determine the Ang III effect on fibronectin produc-
tion, metabolic labeling and immunoprecipitation were
done. Treatment of resting fibroblasts with Ang II and Ang
III (1027 to 10211 M) for 24 hours caused a significant
increase in fibronectin synthesis, with a maximal response
at 1027 M Ang III (155 6 14% increase vs. control (100 6
11, N 5 3; P , 0.05), similar to that observed with Ang II
(165 6 12% increase vs. control, N 5 3, P , 0.05; Fig. 2B).
In some experiments TGF-b (50 pM) was employed as a
positive control (220 6 18% increase vs. control, N 5 3,
P , 0.05). All these data suggest that Ang III, through
TGF-b gene expression and fibronectin production, could
participate in matrix accumulation during renal injury.
Renal cells express angiotensinogen mRNA levels:
Regulation by Ang III and Ang II
Recent studies have shown that renal tubular cells and
interstitial fibroblasts express angiotensinogen mRNA [2,
12]. This gene is also expressed by mesangial cells (Fig. 3),
suggesting that all these cells could contribute to the
generation of angiotensin peptides in the kidney. Ang II
up-regulates angiotensinogen gene expression in the liver,
in cardiac myocytes and in renal interstitial fibroblasts [12,
22]. In cultured mesangial cells, Ang II and Ang III
increased angiotensinogen mRNA expression (2.7- and
2.8-fold, respectively at 1027 M after 6 hr; Fig. 3). Similar
results were observed in renal interstitial fibroblasts (Fig.
3). These results suggest that those peptides could contrib-
ute to an increase in the renal generation of angiotensin
peptides.
Fig. 2. Ang III increases TGF-b1 mRNA expression (A) and fibronectin (FN) synthesis (B). (A) Cells were stimulated with 1027 M Ang III and Ang
II for six hours. A representative Northern blot of two is shown. (B) Renal interstitial fibroblasts were metabolically labeled with 35S-methionine and
stimulated with 1027 M Ang III and Ang II, and 50 pM TGF-b for 24 hours. Figure shows the densitometric analysis of the FN-bands in the upper part
and in the lower part shows a representative autoradiography of PAGE-SDS of FN. Data were shown as percentage of increase versus control in
arbitrary units. Mean 6 SEM of 3 experiments. *P , 0.05 versus control.
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DISCUSSION
Among the peptides of RAS, only Ang II has been
considered as a renal growth factor [1, 2 and the references
therein]. Although Ang III, the N terminal deleted hep-
tapeptide fragment of Ang II, presents some biological
functions, its role in the events associated to progressive
renal diseases has not been evaluated. It is well known that
Ang II activates some short and long growth-related re-
sponses, such as induction of early response genes and cell
proliferation [1, 2]. The effect of Ang II on cell growth is
controversial. In mesangial and vascular smooth muscle
cells, both a hyperplasic or hypertrophic response has been
found [reviewed in 1]. In renal interstitial fibroblasts, we
have recently reported that Ang II increases cell prolifer-
ation [12], while in proximal tubular cells it induces cell
hypertrophy [2]. Nevertheless, those stimulatory effects
were mediated by AT1 receptors, as shown by the employ-
ment of Dup753, a specific nonpeptidic receptor antagonist
[1, 2, 12]. In all of these cell types as well as in in vivo
infusion, Ang II induces c-fos mRNA expression [1, 2, 12].
The c-fos protein acts as a transcriptional factor that
mediates growth response [18]. We have observed that
after one hour of stimulation Ang III induces c-fos gene
expression with an intensity similar to Ang II. Although
future studies are necessary, these results suggest that Ang
III could participate in the control of cell proliferation.
One feature of renal disease is the accumulation of
extracellular matrix production in the glomerulus and
interstitium [10]. In vitro and in vivo studies have demon-
strated that local Ang II could contribute to these phenom-
ena [10–16]. Ang II activates mesangial cells, tubular cells
and, as we have recently shown, renal interstitial fibroblasts
increasing the expression and synthesis of matrix proteins
[1, 2, 12]. These effects seem to be mediated by the release
of transforming growth factor-b (TGF-b) [2]. In experi-
mental models of renal damage associated to elevated renal
Ang II production, an upregulation in renal TGF-b expres-
sion was noted in correlation with increased extracellular
matrix protein mRNA expression and deposition, that
diminished in response to ACE inhibition and AT1 recep-
tor blockade treatment [14–17]. In those settings, an in-
crease in general and specific proteases has been described
[3, 8, 9], suggesting the presence of Ang II degradation
products, such as Ang III that could eventually contribute
to amplify the renal damage. Our studies have shown that
in cultured mesangial cells and renal interstitial fibroblasts
Ang III increased TGF-b mRNA expression and fibronec-
tin production, suggesting that this peptide could also
contribute to the matrix accumulation observed during
renal damage.
Several studies have demonstrated the existence of an
independent tissue RAS in several organs, including the
kidney. During renal injury, an activation of renal RAS and
an increase of local Ang II generation have been observed
in situations associated or not to hypertension [23–25]. In
this sense, in a normotensive model of immune complex
nephritis, we have described an increase in renal ACE
activity and upregulation of renal angiotensinogen mRNA
expression correlated with proteinuria and sclerosis [25]. In
addition, we have observed that in cultured mesangial cells
and renal interstitial fibroblasts angiotensinogen mRNA
expression was up-regulated in response to Ang II and Ang
III, suggesting that these peptides could contribute to the
increased local angiotensin generation, through angio-
tensinogen gene regulation. The expression of this gene is
controlled mainly by two transcription factor families,
NF-kB and CCAAT/enhancer binding protein, which bind
an inducible enhancer in the angiotensinogen gene pro-
moter [22]. Recent data have shown activation of local
NF-kB during tissue damage, including the kidney, that
diminished in response to ACE inhibition [13, 26]. More-
over, in cultured mesangial cells Ang II activates NF-kB
[13]. These data suggest that activation of NF-kB might
also contribute to a sustained synthesis of local angio-
tensins, through angiotensinogen gene expression, and
therefore to a potential further tissue damage.
In summary, our data show that in cultured mesangial
Fig. 3. Ang III up-regulates angiotensinogen gene expression in renal
cells. Mesangial cells and renal interstitial fibroblasts constitutively express
angiotensinogen (Ao) mRNA as shown by RT-PCR. (A) Cells were
stimulated for six hours with 1027 M Ang III and Ang II. A representative
experiment of RT-PCR of three is shown; G3PDH was used as internal
control. (B) Densitometric analysis of the PCR products. Values are
expressed as N-fold of increase versus control, normalized to the respec-
tive G3PDH.
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cells and renal interstitial fibroblasts Ang III elicits overex-
pression of genes involved in renal damage, regulating cell
growth and matrix production. These results support the
hypothesis that Ang II is not the one and only effector
peptide of the RAS, and afford more information to modify
our classical view of this system.
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